Medical advancements must undergo rigorous testing in the form of clinical trials before they can be made available for general use. Phase I and II studies assess safety. Phase III studies determine if new drugs are effective. Clinical trials represent the final stage of cutting edge science and medicine's pursuit of improved treatments.
The Network for Excellence in Neuroscience Clinical Trials, or NeuroNEXT, conducts Phase II studies of treatment for neurological diseases. The network is sponsored by the National Institute of Neurological Disorders and Stroke (NINDS) and is comprised of 25 national clinical sites. Visit our website at www.neuronext.org.
NeuroNEXT Trials Open to Enrollment
- Safety evaluation of 3K3A-APC in ischemic stroke - RHAPSODY
- Safety, Tolerability and Activity in Irritable Subjects with Huntington's Disease - STAIR
- Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme - Cyto-C
NeuroNEXT Completed Trials
- Spinal Muscular Atrophy (SMA) Biomarkers in the Immediate Postnatal Period of Development
- SPRINT-MS: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects with Progressive Multiple Sclerosis
- A Phase II Trial of Rituximab in Myasthenia Gravis - Beat MG
Contact Catherine Canamar, Ph.D.
Neurology Department Clinical Trials
Clinical research activities are ongoing in many subspecialty areas including Alzheimer's disease, epilepsy, multiple sclerosis, amyotrophic lateral sclerosis, neurorehabilitation (stroke and spinal cord injury), and post-polio. For additional clinical trial information, contact the individual program.
Research Contacts and Web Listings of Current Trials by Program
|Alzheimer's Disease||310-794-6039||www.eastonad.ucla.edu www.ftd.ucla.edu|
|Brain Mapping||bmap.ucla.edu semel.ucla.edu|
|Multiple Sclerosis||310-206-2176||www.clinicaltrials.gov www.neuronext.org|
Amyotrophic Lateral Sclerosis
UCLA Principal Investigators may add or update their program's Research Contact, web address, or clinical trial listing on this page. UCLA PIs, click here to email Dr. Canamar your request.